To cause less complement-mediated pain and fewer hypersensitivity reactions than ch14.18. We conducted a phase I trial of hu14.18K322A in children with refractory or recurrent neuroblastoma to define the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and immunogenicity of this novel antiGD2 antibody.PATIENTS AND METHODSPatient Population Eligibil